LON:ARIX - Arix Bioscience Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 256
  • Forecasted Upside: 82.86 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 140
▲ +0.4 (0.29%)

This chart shows the closing price for ARIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arix Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARIX

Analyst Price Target is GBX 256
▲ +82.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Arix Bioscience in the last 3 months. The average price target is GBX 256, with a high forecast of GBX 256 and a low forecast of GBX 256. The average price target represents a 82.86% upside from the last price of GBX 140.

This chart shows the closing price for ARIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Arix Bioscience. This rating has held steady since June 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/12/2021Shore CapitalReiterated RatingHold
7/6/2021Peel HuntReiterated RatingBuyGBX 256
7/6/2021Peel HuntReiterated RatingBuyGBX 256
4/26/2021Shore CapitalReiterated RatingHold
3/10/2021Shore CapitalReiterated RatingBuy
1/18/2021Shore CapitalReiterated RatingBuy
4/6/2020Shore CapitalReiterated RatingUnder Review
10/23/2019Shore CapitalInitiated CoverageBuy
4/11/2019Stifel NicolausReiterated RatingBuy
3/29/2019Jefferies Financial GroupLower Price TargetBuyGBX 288 ➝ GBX 270
2/19/2019Jefferies Financial GroupReiterated RatingBuyGBX 288
8/6/2018Jefferies Financial GroupReiterated RatingBuy
7/18/2018Jefferies Financial GroupBoost Price TargetBuyGBX 268 ➝ GBX 275
11/17/2017Jefferies Financial GroupReiterated RatingBuy
5/15/2017Jefferies Financial GroupInitiated CoverageBuyGBX 245
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Arix Bioscience logo
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.
Read More

Today's Range

Now: GBX 140
Low: 139.65
High: 141

50 Day Range

MA: GBX 160.59
Low: 140
High: 175

52 Week Range

Now: GBX 140
Low: 102
High: 234

Volume

220,017 shs

Average Volume

199,461 shs

Market Capitalization

£180.85 million

P/E Ratio

5.05

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Arix Bioscience?

The following Wall Street sell-side analysts have issued reports on Arix Bioscience in the last year: Peel Hunt, Peel Hunt LLP, and Shore Capital.
View the latest analyst ratings for ARIX.

What is the current price target for Arix Bioscience?

2 Wall Street analysts have set twelve-month price targets for Arix Bioscience in the last year. Their average twelve-month price target is GBX 256, suggesting a possible upside of 82.9%. Peel Hunt has the highest price target set, predicting ARIX will reach GBX 256 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 256 for Arix Bioscience in the next year.
View the latest price targets for ARIX.

What is the current consensus analyst rating for Arix Bioscience?

Arix Bioscience currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARIX will outperform the market and that investors should add to their positions of Arix Bioscience.
View the latest ratings for ARIX.

What other companies compete with Arix Bioscience?

How do I contact Arix Bioscience's investor relations team?

Arix Bioscience's physical mailing address is 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom. The company's listed phone number is +44-20-72901050. The official website for Arix Bioscience is arixbioscience.com.